Related by context. All words. (Click for frequent words.) 79 Factor Receptor 78 Anti Tumor 78 Tyrosine Kinase Inhibitor 77 Signaling Pathway 77 Kinase Inhibitor 77 Prolongs Survival 77 Aurora Kinase 76 Cyclooxygenase 2 76 Monoclonal Antibody 76 Tumor Necrosis Factor 76 Mucosal 76 Mouse Model 76 Antitumor Activity 76 Progenitor Cells 76 Chemokine Receptor 76 myelofibrosis polycythemia vera 76 Novel Mechanism 76 Adjuvant Chemotherapy 76 Immunotherapeutic 76 Androgen Receptor 75 Epratuzumab 75 Antitumor 75 Novel Oral 75 Antiangiogenic 75 Anthracycline 75 Transcription Factor 75 Advanced Renal Cell 75 Shows Promise Against 75 Estrogen Receptor 75 Immune Responses 75 Renal Cell Carcinoma 75 Cardiotoxicity 74 Recombinant Human 74 Disease Progression 74 Protein Kinase C 74 Polymorphisms 74 Inhibits 74 Tumor Suppressor 74 Hormone Refractory Prostate Cancer 74 Receptor Antagonists 74 CYT# potent vascular disrupting 74 Gene Mutation 74 Interferon Beta 74 Cytotoxic T 74 Breast Cancer Cells 74 Adenoma 74 Immunomodulatory 74 Monoclonal 74 Janus kinase 73 Cytotoxic 73 Platelet Derived Growth 73 HER1 73 AnaSpec Introduces 73 Bosutinib 73 Combination Therapy 73 Aliskiren 73 androgen receptor AR 73 Kinase Inhibitors 73 Oncolytic 73 Tumor Targeting 73 Virus Infection 73 CYP#A# CYP#D# 73 Oncogenic 73 Dendritic Cells 73 JAK2 enzyme 73 Anti Tumor Activity 73 Patients Treated With 73 Cell Adhesion 73 Cytochrome P# 73 Fungal Infections 73 Systemic Delivery 73 Tumor Growth 73 Leukemias 73 Inflammatory Diseases 73 Glucocorticoid 73 Drug Candidate 73 Inflammatory Markers 73 Antigens 73 Mutational 73 Improves Survival 73 Receptor Agonist 73 K ras mutations 73 Signaling Pathways 73 Complicated Skin 73 EGFR HER2 73 Adenoviral 73 Cancer Cells 73 protein tyrosine phosphatase 1B 73 Orally Active 73 Endothelial Cells 72 Targeted Therapy 72 Replacement Therapy 72 Cell Proliferation 72 Skeletal Muscle 72 Hepatitis B Virus 72 metastatic colorectal 72 hypereosinophilic syndrome 72 Histone 72 Lymphoid 72 T#I [002] 72 chronic eosinophilic leukemia 72 Drug Shows Promise 72 Meets Primary Endpoint 72 Circulating Tumor Cells 72 Gastric Cancer 72 DNA Methylation 72 Macrophage 72 FLT3 72 Oral Fingolimod 72 CYP#A# substrate 72 mTOR mammalian target 72 Diabetic Neuropathy 72 Mg Usa 72 Inactivation 72 Protein Kinase 72 histone deacetylase inhibitor 72 Sapacitabine 72 See CLINICAL PHARMACOLOGY 72 Malignant Glioma 72 Carcinomas 72 Endometrial 72 Clusterin 72 Interferon gamma 72 Patients Receiving 72 Squamous 72 Smooth Muscle 72 Tigecycline 72 ACE Inhibitors 72 receptor tyrosine kinase 72 Drug Resistant 72 Myelodysplastic Syndromes 72 Mimetics 72 pan HDAC inhibitor 72 EGFr 72 Epithelial 72 Adjuvant Treatment 72 Pooled Analysis 72 Modulates 72 Dehydrogenase 72 Malignant Melanoma 72 Autoimmune Disorders 72 Receptor Antagonist 72 humanized monoclonal 72 Granulocyte Colony Stimulating Factor 72 5 HT6 receptor 72 Unresectable 72 TRAIL R2 72 Dasatinib 71 familial amyloidotic polyneuropathy FAP 71 Induces 71 Enzastaurin 71 erlotinib Tarceva ® 71 Clinical Trial Results 71 Upregulation 71 pathophysiological effects 71 PEGylated Fab fragment 71 Preclinical Study 71 c MET 71 vimentin 71 Combination Treatment 71 Angiogenic 71 Neuroprotective 71 HDAC Inhibitor 71 Transmembrane 71 Cytotoxicity 71 PKC# 71 Vitro Activity 71 Benign Prostatic Hyperplasia 71 Peripheral Blood 71 TTR gene 71 Hormone Receptor Positive 71 Therapeutic Potential 71 Lymphocytic 71 Metastases 71 Anticancer Drugs 71 investigational humanized monoclonal antibody 71 Present Preclinical Data 71 Hsp# Inhibitor 71 Bevacizumab 71 Angiotensin 71 Antifungal 71 selective modulator 71 Cholesterol Lowering Drug 71 Metastatic Prostate Cancer 71 Nicotine Vaccine 71 Fibrinogen 71 metastatic neuroendocrine tumors 71 Clinical Outcome 71 TNF Blockers 71 Progenitor Cell 71 soluble tumor necrosis 71 Gleevec resistant 71 Fulvestrant 71 Genetic Mutation 71 FGFR3 71 dasatinib Sprycel 71 Allogeneic 71 kidney urologic 71 selective kinase inhibitor 71 Breast Cancer Recurrence 71 Hepatocellular Carcinoma 71 dasatinib Sprycel ® 71 Protease Inhibitor 71 Apoptotic 71 Attenuates 71 Aptamer 71 VEGF receptor 71 PDGF receptor 71 Autoantibodies 71 Breast Tumors 71 Bucindolol 71 Antithrombin 71 chimeric monoclonal antibody 71 Lubiprostone 71 Unfractionated Heparin 71 Incretin 71 Blinatumomab 71 IGF1R 71 Methylnaltrexone 71 Improves Outcomes 71 Phase 2b Clinical Trial 71 HIF 1alpha 71 selective inhibition 71 Therapeutic Efficacy 71 complement inhibitor eculizumab 71 BRAF V#E 71 Pertuzumab 71 Anthrax Toxin 71 EGFR tyrosine kinase inhibitors 71 eIF 4E 71 Degarelix 71 Hematopoietic 71 receptor tyrosine kinase inhibitor 71 Respiratory Virus 71 Chemotherapeutic Agents 71 Investigational Agent 71 Previously Treated 71 Preclinical Data 71 Interferon Gamma 71 telomerase reverse transcriptase 71 Epstein Barr Virus EBV 71 Pharmacokinetics PK 71 MAGE A3 ASCI 71 Novel Therapeutic 71 Genetic Variation 71 Small Molecule 71 targeting CD# 71 Recombinant Protein 71 Angiotensin Converting Enzyme 70 Aggressive Prostate Cancer 70 EGF receptor 70 Vaccine Candidate 70 Phospholipase A2 70 Thiazolidinediones 70 Cathepsin B 70 Chronic Lymphocytic Leukemia 70 Reductase 70 Therapeutic Vaccine 70 Leukocyte 70 Subunit 70 Bavituximab 70 cMET 70 Intracellular 70 Aflibercept 70 Therapeutic Antibody 70 Decitabine 70 Advanced Melanoma 70 Immune Cells 70 Demonstrates Efficacy 70 Metabolites 70 Severe Sepsis 70 Genotypes 70 Contrast Agents 70 Potent Anti 70 Novel Antibiotic 70 Fibroblast 70 chemokine receptor 70 Polymerase Inhibitor 70 Glufosfamide 70 ErbB1 70 Epidermal Growth Factor 70 Tumor Response 70 Eculizumab 70 Low Dose 70 Selective Inhibitor 70 Interferons 70 Preclinical Efficacy 70 Phase 2a Clinical Trial 70 Receives Orphan Drug Designation 70 Study Evaluating 70 Immune Cell 70 Improved Survival 70 Refractory Hodgkin Lymphoma 70 IGF IR 70 DNA intercalator 70 Gene Linked 70 Bafetinib 70 IAP inhibitor 70 Adjuvant Therapy 70 Oral Mucositis 70 Myocardial Ischemia 70 RNAi Therapeutic 70 JAK Inhibitor 70 ALN HPN 70 Completes Patient Enrollment 70 poly ADP ribose polymerase 70 Antiviral Activity 70 TNF Tumor Necrosis Factor 70 Gefitinib 70 C Reactive Protein 70 alpha folate receptor 70 Chronic Hepatitis C 70 Kidney Transplant Patients 70 Myeloid 70 Assay Kits 70 Initiate Clinical Trial 70 Analogs 70 Monocytes 70 Phosphorylation 70 Rigel R# 70 Subtypes 70 Locked Nucleic Acid LNA 70 Vidaza azacitidine 70 Improve Survival 70 Transcriptional 70 Presents Preclinical Data 70 Survival Benefit 70 Treating Chronic 70 Metastatic Melanoma 70 Drug Prevents 70 Squamous Cell Carcinoma 70 gefitinib Iressa 70 Chemoradiation 70 SPRYCEL ® 70 Autoimmune Disease 70 Protein Linked 70 Romiplostim 70 Anti Angiogenic 70 Genotyping Test 70 Antisense Oligonucleotides 70 ERK pathway 70 Pegylated 70 Mesenchymal Stem Cells 70 Uric Acid 70 Colorectal Cancer Patients 70 Phase IIb Trial 70 anti CD3 70 Alkaline Phosphatase 70 Relapsed Refractory 70 Progressive Multifocal Leukoencephalopathy 70 Shown Effective 70 Thyroid Hormone 70 E#F# 70 Shows Promising 70 Brain Metastases 70 IgG1 monoclonal antibody 70 Neoplasms 70 retinoic acid receptor 70 Calcitonin 70 Synthase 70 Regenerative Cells 70 flavopiridol 70 Tumor Suppressor Gene 70 Aurora kinase 70 Initiates Clinical Trial 70 5 Fluorouracil 70 Potent Inhibitor 70 5 HT4 70 Peginterferon Alfa 2a 70 Demonstrates Potent 70 Anticancer Activity 70 HDAC enzymes 70 Immunosuppressive 70 Fludarabine 70 Hepatocytes 70 FDA Okays 70 Test Detects 70 GSTP1 70 COX2 70 downstream effector 70 Antigen Specific 70 Tyrosine Kinase 70 Gene Variant 70 Hepatitis C Infection 70 Lowers Risk 70 carcinoembryonic antigen 70 Tumor Cells 70 Diabetic Nephropathy 70 Achieves Primary Endpoint 70 CD# monoclonal antibody 70 Previously Untreated 70 von Willebrand Factor 70 colorectal carcinoma 70 Gene Variation 70 interleukin IL -# 69 Phase 2b Study 69 Statistically Significant 69 Slows Progression 69 Hepatocellular 69 Romidepsin 69 Vascular Endothelial Growth 69 mediated apoptosis 69 Protein Synthesis 69 Transdermal Delivery 69 Parathyroid Hormone 69 Atypical Hemolytic Uremic Syndrome 69 monocytes macrophages 69 Predict Response 69 Protease Inhibitors 69 Radiofrequency Ablation 69 Combo Therapy 69 Treatment Naïve 69 hepatoma 69 Prostatic 69 novel VDA molecule 69 Allergic Rhinitis 69 Differentially 69 Breast Cancer Metastasis 69 Antiarrhythmic 69 Inhaled Corticosteroids 69 TRAIL R1 69 Erlotinib 69 cyclin dependent kinase inhibitor 69 TNFα 69 Lung Cancer Drug 69 Metastatic Colorectal Cancer 69 Neuroprotection 69 Ischemic 69 proteasome inhibitors 69 Synthetic Peptide 69 Akt activation 69 Randomized Phase 69 peptidic compound 69 Adefovir 69 orally administered inhibitor 69 LRP5 69 Pemetrexed 69 Irinotecan 69 Prophylactic Treatment 69 liposomal formulation 69 cyclin E 69 myelodysplastic myeloproliferative diseases 69 B Cell Lymphoma 69 Maribavir 69 thalidomide Thalomid 69 Cutaneous T 69 NS#/#A protease 69 Proteasome 69 Sipuleucel T 69 Combination REOLYSIN R 69 Prodrug 69 Shows Efficacy 69 Treatment Shows Promise 69 HER2 Positive 69 HER2/neu 69 Trial Evaluating 69 Hypertensive Patients 69 Septic Shock 69 matrix metalloproteases 69 Ovarian Cancers 69 Systemic lupus erythematosus SLE 69 Slow Progression 69 Treatment Reduces 69 adipogenic 69 Myelofibrosis 69 agonistic human 69 Genes Involved 69 D aspartate NMDA receptor 69 Is Well Tolerated 69 Pralatrexate 69 fosbretabulin 69 Placebo Controlled Trial 69 histone deacetylase HDAC inhibitor 69 Left Ventricular 69 Neuroendocrine Tumors 69 TNFalpha 69 Investigational Compound 69 Traficet EN 69 Hypoxia Inducible Factor 69 Itraconazole 69 monoclonal antibody MAb 69 epithelial tumors 69 Prostate Cancers 69 Histone Deacetylase 69 sodium glucose cotransporter 69 cell adhesion molecule 69 cytostatic 69 Nedd4 69 Chronic Lymphocytic Leukemia CLL 69 Genetic Variant 69 Azacitidine 69 Naive Patients 69 lexidronam injection 69 Pulmonary Arterial Hypertension 69 Apaziquone 69 Liposomal 69 Lung Cancer Patients 69 Files IND 69 Spinal Fluid 69 Fracture Risk 69 MTP inhibitor 69 Flt3 69 Disease Modifying 69 Transdermal Patch 69 Chronic HCV 69 Castration Resistant Prostate Cancer 69 Lung Cancer Survival 69 vapreotide acetate 69 metastatic malignant 69 Nucleoside 69 Genes Linked 69 Thrombin 69 interferon γ 69 Adenomas 69 rhIL 7 69 5alpha reductase 69 MGd 69 5 HT6 69 platform HDL Mimetic 69 Small Intestine 69 Daclizumab 69 Breast Cancers 69 Phase IIa Clinical Trial 69 Immunosuppression 69 Anti VEGF 69 Safinamide 69 JAK2 Inhibitor 69 Ecallantide 69 multi kinase inhibitor 69 treat benign prostatic 69 M2 subunit 69 Prospective Randomized 69 Th1 type 69 Elotuzumab 69 Deforolimus 69 Renal Cell Cancer 69 HER2 overexpression 69 γ secretase 69 Anticancer Agent 69 cisplatin resistant 69 sunitinib Sutent ® 69 thymidylate synthase TS 69 inducible nitric oxide synthase 69 targeted antifolate 69 MKC# MT 69 immunostimulatory 69 CCX# 69 Vascular Inflammation 69 MDR1 69 Induces Apoptosis 69 Antisense 69 HER2 receptor 69 Novel Small Molecule 69 Premature Aging 69 proteasome inhibitor 69 Investigational Treatment 69 Tyrosine Kinase Inhibitors 69 Darinaparsin 69 Pharmacodynamics 69 Elderly Patients 69 Tezampanel 69 Blood Pressure Drug 69 Medullary Thyroid Cancer 69 GW# [003] 69 R Saizen R 69 Demonstrates Significant 69 Suppresses 69 Lupus Nephritis 69 Predict Risk 69 Stem Cell Transplants 69 SPINK1 69 hypoxia inducible factor 69 Novel Inhibitor 69 G Protein Coupled 69 RhuDex R 69 Secretase 69 effector function 69 Epitope 69 Retinoic Acid 69 Basal Cell 69 Prognostic Factors 69 Phase 2a Trial 69 Novel Protein 69 Gene Variants 69 tumor xenograft models 69 Phase 2b Trial 69 Talabostat 69 TNF Alpha 69 NS5b 69 leukotriene pathway 69 Transgenic Mice 69 Cell Transplants 69 PDGFR 69 Mutation Detection 69 Rheumatoid Arthritis Patients 69 Prostate Cancer Progression 69 Gleevec imatinib mesylate 69 Soft Tissue Sarcoma 69 Transcriptome 69 Cervical Dysplasia 69 Epitopes 69 colorectal carcinomas 69 Mg Uk 69 antiproliferative effects 69 tyrosine kinase receptor 69 5 HT2A serotonin 69 Well Tolerated 69 Anti Inflammatory Drug 69 Nymox NX 69 Vaccine Protects Against 69 Monocyte 68 Appears Safe 68 Monoamine Oxidase 68 Enzyme Replacement Therapy 68 MAGE A3 68 demethylating agent 68 Long Term Efficacy 68 Pharmacokinetic Study 68 MCSP respectively 68 candidates Azedra TM 68 antisense inhibitor 68 NSCLC tumors 68 Advanced Prostate Cancer 68 Kinases 68 Radiation Induced 68 Viral Infections 68 Fondaparinux 68 MEK ERK 68 Node Positive 68 oral Janus kinase 68 Lung Cancers 68 Effectively Treats 68 Plasmid DNA 68 GRNOPC1 contains 68 anaplastic lymphoma kinase ALK 68 Successfully Completes Phase 68 HER2 Positive Breast Cancer 68 Autologous Stem Cell Transplantation 68 Cannabinoid 68 Cytomegalovirus CMV 68 Cerebrospinal Fluid 68 Invasive Fungal Infections 68 Demonstrated Significant 68 Bortezomib 68 Breast Cancer Stem Cells 68 Hypercholesterolemia 68 uricase 68 imatinib Gleevec ® 68 Enlarged Prostate 68 Novel Anticancer 68 vinca alkaloids 68 Papillary 68 antisense inhibitors 68 promoter methylation 68 selective antagonist 68 accumulate preferentially 68 MicroRNA 68 LPA1 receptor 68 Janus Kinase 68 Monotherapy 68 Tubulin 68 Shows Statistically Significant 68 Albuferon TM 68 Reduced Risk 68 HAAH 68 oral prodrug 68 Chronic Sinusitis 68 siRNA Delivery 68 Rheumatoid Arthritis Drug 68 alpha#beta# integrin 68 IL 1ß 68 FGFR1 68 interferon IFN 68 Non Steroidal Anti Inflammatory 68 mertansine 68 NS4A 68 Epithelial Cell 68 Nilotinib 68 multikinase inhibitor 68 Lentiviral 68 Randomized Study 68 Integrin 68 targeted radiotherapeutic 68 Interferon Alpha 68 gastrointestinal stromal tumors GISTs 68 Angiotensin II 68 NKG2D 68 antibody MAb 68 NPM1 mutation 68 Metastatic Renal Cell Carcinoma 68 somatostatin receptors 68 Initiates Clinical 68 PI3K Akt 68 Controlled Trial 68 neuroblastoma tumors 68 SGLT2 68 Prostate Tumors 68 Initiates Enrollment 68 Trastuzumab 68 Controlled Study 68 Single Dose 68 Receptors GPCRs 68 sulindac 68 Endothelial 68 sorafenib tablets 68 Factor VEGF 68 Drug Combo 68 Dose Escalation 68 Factor VIIa 68 Preclinical Models 68 Levels Linked 68 mitogen activated protein kinase 68 ERBB2 68 phosphatidylinositol 3 68 Quantitation 68 azacytidine 68 Gamma secretase 68 Temsirolimus 68 Solid Tumors 68 Vorinostat 68 PTPN# 68 R lenalidomide 68 SensoLyte ® 68 Glucocorticoids 68 Tumor Cell 68 reverse transcriptase inhibitors 68 Androgen Deprivation Therapy 68 Intravascular 68 receptor modulators 68 Radioimmunotherapy 68 ABCB1 68 Subtype 68 LRP6 68 antibody MT# 68 T#M 68 EGFR TK 68 VIPR2 68 tumor necrosis 68 Insulin Resistance 68 Anticancer Drug 68 Binding Protein 68 Novel Compound 68 Hormone Receptor 68 extracellular signal 68 Voreloxin 68 NKX#.# 68 Ozarelix 68 Oritavancin 68 Chemotherapy Induced 68 Neoadjuvant Chemotherapy 68 KRAS mutation 68 Dose Finding 68 CD# CD# 68 Non Invasive Treatment 68 Fewer Side Effects 68 Inhibitory 68 Luteinizing Hormone Releasing Hormone 68 apoptosis proteins 68 Influenza Virus 68 Anti Phospholipid Therapy 68 ERK1 2 68 Inflammatory Disease 68 Atypical Antipsychotic 68 alkylating agent 68 investigational monoclonal antibody 68 bevacizumab Avastin ® 68 benzimidazole 68 apoptotic pathway 68 phosphorylates 68 TNF α 68 P#X# 68 Gram Positive 68 Vidaza ® 68 AT1R 68 Bone Morphogenetic Protein 68 IND Application 68 RNAi Therapeutics 68 microtubule inhibitor 68 Taxane 68 Antibacterials 68 Lenalidomide 68 Boceprevir 68 mitochondrial toxicity 68 Monoclonal Antibodies 68 vinca alkaloid 68 HER2 ErbB2 68 Secretion 68 systemic fungal infections 68 DNA methyltransferases 68 Denufosol 68 Catheter Associated 68 BAL# [001] 68 ADP receptor antagonist 68 Faropenem 68 reversible inhibitors 68 Randomized Phase II 68 Pegylated Interferon 68 C5aR 68 Taxanes 68 Chemotherapeutic 68 adalimumab Humira 68 S#P# 68 Prognostic Value 68 Prostate Cancer Recurrence 68 Pivotal Phase 68 Mouse Models 68 Chronic Hepatitis B 68 ALN TTR 68 MEK Inhibitor 68 Bazedoxifene 68 LHRH 68 Hedgehog Pathway 68 Demonstrates Positive 68 Bladder Cancer 68 Myocardial Perfusion Imaging 68 Placebo Controlled Study 68 Omacetaxine 68 Gout Drug 68 RNA Interference 68 serine threonine kinase 68 Teva Provides Update 68 Atopic Dermatitis 68 Phase III Clinical Trial 68 Zollinger Ellison Syndrome 68 tubulin binding 68 Thiovir 68 Diffuse Large B 68 Calcineurin 68 nucleoside analog 68 Diabetic Foot Ulcer 68 Nucleic Acid 68 replicon 68 HER2 HER3 68 myeloperoxidase 68 GNAQ 68 PDE# 68 FGFR 68 TNF receptors 68 Protein Expression 68 Pathway Inhibitor 68 EGFR tyrosine kinase inhibitor 68 Aplidin R 68 engineered RAP peptides 68 essential thrombocythemia ET 68 Glycosylation 68 potent antiproliferative 68 TRAIL receptors 68 Capecitabine 68 receptor partial agonist 68 Trabectedin 68 NS5B polymerase 68 Secretory 68 Diabetic Neuropathic Pain 68 Resistant Hypertension 68 Nanoemulsion 68 Alfacell proprietary ribonuclease 68 Anticonvulsant 68 Peginterferon alfa 2b 68 Gastrointestinal Stromal Tumors 68 dopamine D2 68 CYP#C# [002] 68 Metabolic Disorder 68 NFkB 68 Antidepressants Linked 68 FGFR4 68 D aspartic acid 68 syngeneic 68 nicotinic acetylcholine receptor 68 huC# DM4 68 HER3 68 antiangiogenesis 68 Survivin 68 Endometrial Cancer 68 Myeloma Patients 68 Organ Rejection 68 somatostatin analogue 68 signal transduction inhibitors 68 Personalized Immunotherapy 68 potently inhibit 68 CEA CD# Her2 68 Hyperlipidemia 68 Neoadjuvant 68 IL #E 68 Localized Prostate Cancer 68 Inhibitor 68 Cancer Vaccines 68 Inflammatory Arthritis 68 dihydrofolate reductase 68 Reverse Transcriptase 68 glycopeptide 68 Psoriasis Drug 68 Chronic Myeloid Leukemia 68 CDK inhibitor 68 vesicular monoamine transporter 68 A3 adenosine receptor 68 Dapagliflozin 68 Efficacy Trial 68 VEGF inhibitors 68 Antifungals 68 Genes Predict 67 Cyclin Dependent 67 WT1 67 Antibody Drug Conjugate 67 Multidrug Resistance 67 NF kB pathway 67 Tesamorelin 67 ritonavir boosted 67 Antiviral Therapy 67 Patients Undergoing 67 diclofenac Voltaren 67 Mutation Analysis 67 Tacrolimus 67 apoptosis inducing 67 PEGylated anti 67 Malignancies 67 Intravenous Human 67 Prodrugs 67 Human Monoclonal Antibody 67 Genes Identified 67 Epilepsy Drug 67 Beta Amyloid 67 Fluorouracil 67 p# mitogen activated 67 EZN 67 Investigational Drug 67 Diagnostic Tests 67 mda 7 67 mitogenic 67 antifibrotic 67 Artery Disease 67 V#F mutation 67 Renal Cancer 67 Vidofludimus 67 Tiotropium 67 Eg5 67 Conjugated 67 IV Busulfex 67 Zorbtive TM 67 Malignancy 67 Recurrent Breast Cancer 67 Colorectal Adenomas 67 c MYC 67 Bacterial Infections 67 Idiopathic Pulmonary Fibrosis 67 Oligonucleotide 67 Integrase 67 PNP inhibitor 67 aberrantly activated 67 HuMax 67 Protease 67 Anti angiogenic 67 Paraplatin ® 67 Protein Interactions 67 PPARgamma 67 Vaccine Adjuvant 67 Everolimus 67 serine protease 67 downregulates 67 Glioblastoma Multiforme 67 Cardiac Function 67 Microalbuminuria 67 luteinizing hormone releasing 67 immune modulatory 67 NMDA antagonists 67 Receptor Signaling 67 Fludara ® 67 vaginal candidiasis 67 Treatment Regimen 67 cytoprotective 67 prostaglandin D2 67 Dose Response 67 MTHFR 67 Intracranial Aneurysms 67 Mesothelin 67 NMDA Receptor 67 Antiplatelet 67 Coronary Arteries 67 Develop Novel 67 novel peptide 67 Androgen 67 vWF 67 HepG2 cells 67 Secondary Hyperparathyroidism 67 Oral Anticoagulant 67 Cholinesterase Inhibitors 67 Liver Injury 67 Asthma COPD 67 polyglutamate 67 immunomodulatory agents 67 humanized antibody 67 T#M mutation 67 tumorigenicity 67 Pivotal Phase III 67 Bisphosphonate 67 Orally administered 67 ErbB3 67 molecule epidermal 67 Overactive Bladder 67 cytotoxic effects